- Home
- CTMX vs CNNE Comparison
CTMX vs CNNE Comparison
Compare CTMX & CNNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTMX | CNNE |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 596.2M | 608.0M |
| IPO Year | 2015 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CTMX | CNNE |
|---|---|---|
| Price | $4.44 | $10.92 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 3 |
| Target Price | $11.90 | ★ $21.33 |
| AVG Volume (30 Days) | ★ 9.4M | 709.7K |
| Earning Date | 03-16-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 5.54% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $76,201,000.00 | ★ $499,700,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $27.22 | N/A |
| P/E Ratio | $22.58 | ★ N/A |
| Revenue Growth | N/A | ★ 3.37 |
| 52 Week Low | $0.40 | $10.82 |
| 52 Week High | $8.21 | $21.96 |
Technical Indicators
Market Signals| Indicator | CTMX | CNNE |
|---|---|---|
| Relative Strength Index (RSI) | 44.37 | 30.81 |
| Support Level | $3.55 | N/A |
| Resistance Level | $6.20 | $16.41 |
| Average True Range (ATR) | 0.60 | 0.40 |
| MACD | -0.07 | 0.02 |
| Stochastic Oscillator | 3.23 | 10.66 |
Price Performance
Historical ComparisonAbout CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
About CNNE Cannae Holdings Inc.
Cannae Holdings Inc is a holding company that manages and operates a group of companies and investments. The company's reportable segments are Restaurant Group, Dun & Bradstreet, Alight, BKFC, Corporate and Other. Majority of the company's revenue is generated from its Restaurant Group segment which represents the operations of O'Charley's and Ninety Nine Restaurants.